193 related articles for article (PubMed ID: 16040807)
1. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor.
Zhou H; Luo Y; Lo JF; Kaplan CD; Mizutani M; Mizutani N; Lee JD; Primus FJ; Becker JC; Xiang R; Reisfeld RA
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10846-51. PubMed ID: 16040807
[TBL] [Abstract][Full Text] [Related]
2. A DNA-based cancer vaccine enhances lymphocyte cross talk by engaging the NKG2D receptor.
Zhou H; Luo Y; Kaplan CD; Krüger JA; Lee SH; Xiang R; Reisfeld RA
Blood; 2006 Apr; 107(8):3251-7. PubMed ID: 16368879
[TBL] [Abstract][Full Text] [Related]
3. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
4. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
[TBL] [Abstract][Full Text] [Related]
5. Immunology. Stress, NK receptors, and immune surveillance.
Pardoll DM
Science; 2001 Oct; 294(5542):534-6. PubMed ID: 11567108
[No Abstract] [Full Text] [Related]
6. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
9. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts.
Ogasawara K; Benjamin J; Takaki R; Phillips JH; Lanier LL
Nat Immunol; 2005 Sep; 6(9):938-45. PubMed ID: 16086018
[TBL] [Abstract][Full Text] [Related]
10. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
11. Strategies for target cell recognition by natural killer cells.
Diefenbach A; Raulet DH
Immunol Rev; 2001 Jun; 181():170-84. PubMed ID: 11513138
[TBL] [Abstract][Full Text] [Related]
12. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
13. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.
Radaeva S; Sun R; Jaruga B; Nguyen VT; Tian Z; Gao B
Gastroenterology; 2006 Feb; 130(2):435-52. PubMed ID: 16472598
[TBL] [Abstract][Full Text] [Related]
14. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
[TBL] [Abstract][Full Text] [Related]
15. Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors.
Rettman P; Blunt MD; Fulton RJ; Vallejo AF; Bastidas-Legarda LY; España-Serrano L; Polak ME; Al-Shamkhani A; Retiere C; Khakoo SI
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016721
[TBL] [Abstract][Full Text] [Related]
16. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
17. UL16 binding proteins.
Cao W; He W
Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
[TBL] [Abstract][Full Text] [Related]
18. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens.
Rice J; Dunn S; Piper K; Buchan SL; Moss PA; Stevenson FK
Cancer Res; 2006 May; 66(10):5436-42. PubMed ID: 16707472
[TBL] [Abstract][Full Text] [Related]
19. Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells.
Rabinovich BA; Li J; Shannon J; Hurren R; Chalupny J; Cosman D; Miller RG
J Immunol; 2003 Apr; 170(7):3572-6. PubMed ID: 12646619
[TBL] [Abstract][Full Text] [Related]
20. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
Zhang C; Zhang J; Wei H; Tian Z
Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]